Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
36.2(c) 36.91(c) 37.15(c) 38.69(c) 40.34 Last
225 693 338 311 345 321 206 651 377 600 Volume
+2.49% +1.96% +0.65% +4.15% +4.26% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -216 M - -
Net cash position 2021 558 M - -
P/E ratio 2021 -24,8x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -259 M - -
Net cash position 2022 629 M - -
P/E ratio 2022 -22,6x
Yield 2022 -
Capitalization 5 844 M 5 844 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 148
Free-Float 81,0%
More Financials
Company
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company combines an understanding of disease-related biology and neurocircuitry of the brain with chemistry and central nervous system (CNS), receptor pharmacology to discover and design new therapies. The Company is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, epilepsy and... 
More about the company
Ratings of Cerevel Therapeutics Holdings, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
10/20CEREVEL THERAPEUTICS : to Report Third Quarter 2021 Financial Results on Wednesday, Novemb..
AQ
10/08CEREVEL THERAPEUTICS : Jefferies & Co Adjusts Cerevel Therapeutics Holdings PT to $37 From..
MT
10/07CEREVEL THERAPEUTICS : R&D Day Presentation
PU
10/07CEREVEL THERAPEUTICS : Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apath..
GL
10/07Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apat..
CI
09/21CEREVEL THERAPEUTICS : Announces Departure of CFO Kathy Yi (Form 8-K)
PU
09/21CEREVEL THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers, Regulatio..
AQ
09/21CEREVEL THERAPEUTICS : CFO Kathy Yi Steps Down; Mark Bodenrader Named Interim CFO
MT
09/21CEREVEL THERAPEUTICS : Announces Departure of CFO Kathy Yi
AQ
09/21Cerevel Therapeutics Holdings, Inc. Announces Executive Changes
CI
09/07CEREVEL THERAPEUTICS : Morgan Stanley Adjusts Cerevel Therapeutics Holdings PT to $39 From..
MT
09/01CEREVEL THERAPEUTICS : to Present at Upcoming Virtual Investor Conferences
AQ
08/11CEREVEL THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/11CEREVEL THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Updates ..
PU
08/11CEREVEL THERAPEUTICS : Corporate Presentation
PU
More news
News in other languages on CEREVEL THERAPEUTICS HOLDINGS, INC.
09/21La directrice financière de Cerevel Therapeutics, Kathy Yi, quitte ses fonctions ; Mark..
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | CERE | US15678U1280 | MarketScreener
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 40,34 $
Average target price 34,75 $
Spread / Average Target -13,9%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.143.31%5 605
GILEAD SCIENCES, INC.15.41%83 993
BIONTECH SE241.44%69 162
WUXI APPTEC CO., LTD.24.51%65 142
REGENERON PHARMACEUTICALS18.47%59 196
VERTEX PHARMACEUTICALS-22.35%48 536